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Background: Multidrug drug resistant Tuberculosis (MDR-TB) and extensively drug resistant Tuberculosis (XDR-TB)
have emerged as significant public health threats worldwide. This systematic review and meta-analysis aimed to
investigate the effects of community-based treatment to traditional hospitalization in improving treatment success
rates among MDR-TB and XDR-TB patients in the 27 MDR-TB High burden countries (HBC).
Methods: We searched PubMed, Cochrane, Lancet, Web of Science, International Journal of Tuberculosis and Lung
Disease, and Centre for Reviews and Dissemination (CRD) for studies on community-based treatment and
traditional hospitalization and MDR-TB and XDR-TB from the 27 MDR-TB HBC. Data on treatment success and failure
rates were extracted from retrospective and prospective cohort studies, and a case control study. Sensitivity analysis,
subgroup analyses, and meta-regression analysis were used to explore bias and potential sources of heterogeneity.
Results: The final sample included 16 studies involving 3344 patients from nine countries; Bangladesh, China,
Ethiopia, Kenya, India, South Africa, Philippines, Russia, and Uzbekistan. Based on a random-effects model, we
observed a higher treatment success rate in community-based treatment (Point estimate = 0.68, 95 % CI: 0.59 to 0.
76, p < 0.01) compared to traditional hospitalization (Point estimate = 0.57, 95 % CI: 0.44 to 0.69, p < 0.01). A lower
treatment failure rate was observed in community-based treatment 7 % (Point estimate = 0.07, 95 % CI: 0.03 to 0.10;
p < 0.01) compared to traditional hospitalization (Point estimate = 0.188, 95 % CI: 0.10 to 0.28; p < 0.01). In the
subgroup analysis, studies without HIV co-infected patients, directly observed therapy short course-plus (DOTS-Plus)
implemented throughout therapy, treatment duration > 18 months, and regimen with drugs >5 reported higher
treatment success rate. In the meta-regression model, age of patients, adverse events, treatment duration, and lost
to follow up explains some of the heterogeneity of treatment effects between studies.
Conclusion: Community-based management improved treatment outcomes. A mix of interventions with DOTS-
Plus throughout therapy and treatment duration > 18 months as well as strategies in place for lost to follow up and
adverse events should be considered in MDR-TB and XDR-TB interventions, as they influenced positively, treatment
success.
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Multidrug resistant tuberculosis (MDR-TB) and exten-
sively drug resistant tuberculosis (XDR-TB) have emerged
as significant public health threats and pose a significant
risk to the control of tuberculosis (TB) worldwide [1].
Globally, an estimated 3.3 % of new TB cases and 20 % of
previously treated cases become multidrug resistant [1]. In
2014, there were about 480,000 new cases of MDR-TB
worldwide and approximately 190,000 deaths from the
disease. An estimated 9.7 % of people with MDR-TB have
XDR-TB [1].
Treatment for drug resistant TB patients has focused on
hospital and ambulatory based management [2–4]. The
rationale for this has been to monitor complex drug regi-
mens, optimize adherence, and limit community transmis-
sion [5]. Centralized interventions can be advantageous, as
they concentrate on MDR-TB cases from larger regions
and allow for management by trained experts in low-
prevalence settings [6]. Despite the effectiveness of central-
ized interventions, hospital and ambulatory based manage-
ment have limitations such as the need for monthly follow
up visits, increased economic and social costs involved in
keeping patients isolated in hospitals and long waiting lists
of TB patients needing treatment [7–10]. Additionally, in-
adequate human resources to deliver treatment and care,
insufficient bed capacity to hospitalize all new patients, and
the difficulty in retaining and monitoring patients on dis-
charge at the end of the intensive phase [7–10] have con-
tributed to poor treatment success rates and increasing lost
to follow up. Due to limited healthcare resources and long-
term treatment regimens, community-based treatment has
been utilized as an alternative care model to hospital-based
treatment [10–12].
Community-based management of MDR-TB incorpo-
rates two key strategies: decentralization of hospital care
from a distant specialist unit to a local district hospital and
early discharge of MDR-TB patients into the community.
Decentralization is achieved by the development of infra-
structure for in-patient care at a district level hospital and
skills transfer from the specialist referral unit [13]. Several
studies [5, 6, 14] have utilized a mix of interventions for
community management of drug resistant tuberculosis
(DR-TB) treatment, which includes utilization of family
members and healthcare workers to administer DOTS-
Plus, social assistance, support groups, routine home visits,
and clinician support at the community-based sites.
Findings from several studies [10, 15–17] suggest the
impact of community-based treatment to be more effect-
ive than care in a traditional hospitalization setting,
grounded on improved treatment success rate, lower lost
to follow up, and shorter time to treatment initiation.
Also, community-based treatment has been shown to in-
crease access to care by improving access to diagnostic
and treatment services to further strengthen treatmentsuccess rate [10–12]. The delivery of community-based
TB treatment through community health workers has
further improved access and service utilization of health-
care [10–12]. Thus, community-based treatment has fa-
cilitated access to treatment by making treatment closer
to patient’s home, and enhancing support to patients
and their families. Community-based management of
MDR-TB is considered vital and cost effective [18] espe-
cially in low resource settings.
So far, only one meta-analysis has focused on compar-
ing community-based treatment to hospitalized treat-
ment for DR-TB [19]. Although, another study (not a
meta-analysis) has compared treatment outcomes in
community-based care versus centralized hospitalization
in South Africa [15], however, more evidence is required
in determining the influence of community-based treat-
ment in bringing about increased treatment success rate.
We carried out a systematic review and meta-analysis to
compare the effectiveness of community-based manage-
ment to traditional hospitalization in the care of patients
with MDR-TB and XDR-TB patients in the 27 MDR-TB
HBC.
Methods
Search strategy and selection criteria
We searched PubMed, Cochrane, Lancet, and Centre for
Reviews and Dissemination (CRD), Web of Science, and
the International Journal of Tuberculosis and Lung Disease
for studies published from January 2005 to October 2015.
Searches were done from September 1, 2015 to October 31,
2015. The search included MeSH terms for MDR-TB and
XDR-TB, “community DOTS-Plus” or “community health
services” or “decentralized” or “home based care” and
“hospitalization” or “centralized” or “in patient”.
We included retrospective cohorts, prospective countries,
and a case control study implementing community-based
and hospitalized treatment in MDR-TB and XDR-TB pa-
tients aged >18 years in the 27 MDR-TB HBC. Studies were
included if they were published in English language, had at
least ten patients in each study group, and patients were
treated for a minimum of six months. For authors having
more than one article on the topic, the most recent article
was accepted or if the content was found different after re-
view, then the other studies were also accepted. Studies
were excluded if the study design was cross sectional or
qualitative or did not report data that were useful for ex-
traction. Studies with a sample size < 10, active TB cases,
utilized surgical interventions, and exclusively used first line
therapy in their treatment protocol were also excluded.
Studies were considered community-based if the model
of care was implemented in a decentralized setting, utilized
family members, and local healthcare workers to directly
observe treatment. For traditional hospitalization, our selec-
tion criteria included implementation in a centralized
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visits to a healthcare facility.
Screening and data extraction
Titles and abstracts of all articles were screened and re-
trieved by AOW and MO to identify potentially eligible
studies. AOW and MO reviewed the full text of poten-
tially eligible articles. These were evaluated using the in-
clusion and exclusion criteria. Database search results
were imported into PubMed Bibliography, ProQuest Flow,
and duplicate records were removed. Reasons for the ex-
clusion of studies are documented and presented in Fig. 1.
Information on the study characteristics and the primary
treatment outcome of interest (treatment success rate or
treatment failure rate) was extracted into Systematic Re-
view Data Repository (SRDR) tool. Additionally, informa-
tion on relevant treatment characteristics (adverse rate,
default rate, regimen model, regimen duration, location,
and provider) was extracted. These outcomes were only
extracted when provided in studies.
Treatment failure rate was defined as the proportion
of patients that failed MDR-TB or XDR-TB treatment,
whereas treatment success rate was defined as theFig. 1 PRISMA Study flowchartproportion of patients that completed MDR-TB or XDR-
TB treatment and cured. Adverse rate was defined as
the proportion of patients who suffered an adverse event
or if a medical decision was made to terminate treat-
ment due to poor response. Lost to follow up was de-
fined as the proportion of patients that interrupted
DR-TB treatment for two or more consecutive months
for any reason.
To minimize potential errors, included articles and the
SRDR data extraction template were reviewed repeat-
edly. When uncertainty arose with deciding the inclusion
of studies, opinion of experts implementing DR-TB pro-
grams in Nigeria were sought. This only occurred twice
throughout the duration of the study.
Assessment of risk of bias within and across included
studies
Since studies were observational, the methodological quality
of each study was determined using the Newcastle-Ottawa
Quality Assessment Scale (NOS) scale and the Strengthen-
ing the Reporting of Observational Studies in Epidemiology
(STROBE) statement [20, 21]. In the NOS scale, a max-
imum of nine points is assigned to cohort studies and eight
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urement of exposure and outcomes, and selection of partic-
ipants. Studies with NOS score < 4 were deemed low
quality, 4–5 as moderate quality, and ≥ 6 as high quality.
Furthermore, the risk of bias across studies was assessed
using the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) system. Studies
were classified as low (observational study), and very low
(any other evidence). According to Higgins and Green [22],
definitions of GRADE of evidence include;
 High: Further research is very unlikely to change
confidence in the estimate of effect
 Moderate: Further research is likely to have an
important impact on the confidence in the estimate
of effect and may change the estimate
 Low: Further research is very likely to have an
important impact on our confidence in the estimate
of effect and is likely to change the estimate
 Very low quality: We are very uncertain about the
estimate
Furthermore, the Cochrane Collaboration’s handbook
was used to assess whether certain steps were taken to
reduce the risk of bias under six domains [23]. Domains
include allocation concealment, blinding, incomplete
outcome data, and sequence generation, selective out-
come reporting and other sources of bias. Judgment was
categorized as yes (low risk of bias) and no (high risk of
bias) or unclear.
Data synthesis and analysis
Using a random effects model, a one-arm meta-analysis
was conducted using Open Meta-Analyst (OMA) software
to analyze and record data from the included studies [24].
Due to the nature of data from eligible studies (i.e. cases
without controls or comparison groups), a one-arm meta-
analysis was suitable. Thus, the odds ratio could not be
used to estimate the strength of association rather the use
of proportion was suitable. Meta-analysis was performed
by analyzing separately and comparing studies classified as
community based and hospitalization that reported out-
comes on treatment success and treatment failure.
Data are presented graphically using the forest plot, in
which the proportion, its 95 % CI, and the overall sum-
mary statistic was estimated [25]. Under the assumption
of the random effects model, estimates of tau square
(tau2), Q statistic, and I square statistic (I2) were generated
and used to evaluate heterogeneity [25]. An I2 value of
50 % or greater and where P < 0.05 was used to denote
high heterogeneity [26]. Meta-regression analysis was con-
ducted to assess whether effect estimates differed by pa-
tient age, adverse effect, default rate, and treatment
duration, thus explaining any of the heterogeneity in thestudy [25, 27]. The dependent variable was DR-TB success
rate and all 9 studies that implemented community-based
treatment were included. The analysis was based on a sig-
nificance at alpha 0.05 level.
Sensitivity analysis using trim and fill was conducted to
further explain the heterogeneity observed [28]. The po-
tential for publication bias was considered by assessing a
visual inspection of the funnel plot symmetry, Begg’s re-
gression, and Egger linear regression test. Additionally,
subgroup analysis was conducted to investigate heterogen-
eity and determine if outcomes differ on several study and
intervention characteristics. The Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement was adhered to in this review [29].
Results
Our search identified a total of 89 publications, of which
21 were duplicates (Fig. 1). Of the 68 articles screened,
23 articles were not eligible and excluded. Full text of 45
articles was reviewed, of which 29 articles were excluded
due to the following reasons: qualitative study design,
meta-analysis review, mode of treatment, and desired
outcomes not reported. One study was not found be-
cause it was not available on CRD as at the time of the
search. In total 16 studies from 9 MDR-TB HBC
(Bangladesh, China, Ethiopia, Kenya, India, South Africa,
Philippines, Russia, and Uzbekistan) met the inclusion
criteria for this study.
Study characteristics
Table 1 shows the summary characteristics of the 16
studies included in the meta-analysis. Nine studies [6,
11, 14, 30–35] implemented a community-based inter-
vention while seven studies [36–42] implemented trad-
itional hospitalization. The sample size for each category
of patients includes: XDR-TB (29), MDR-TB & XDR-TB
(807) and MDR-TB (2508). Twelve studies [6, 11, 14, 31,
33–36, 39–42] included MDR-TB patients, three studies
[30, 32, 37] had both MDR and XDR TB patients, and
one study [38] included only XDR-TB patients.
Eight studies [30–32, 36, 38, 40–42] utilized healthcare
workers, two studies [6, 11] utilized a combination of
home care support teams and families, two studies [33, 35]
used both healthcare workers and family, and one study
each used home care support teams (14) and family [34] as
a DOTS-Plus provider. For treatment of DR-TB patients,
nine studies [6, 11, 30, 31, 33–36, 39, 42] utilized standard-
ized treatment and six used individualized regimen [31, 32,
37, 38, 40, 41]. Treatment duration for the intensive and
continuous phase ranged from 4 to 6 months and 12–27
months. Eleven studies [11, 30–32, 34, 35, 37–39, 42] used
at least five drugs and two studies [6, 33] used six drugs in
their treatment regimen. In addition, DOTS-Plus was ob-
served throughout therapy in 9 studies [6, 11, 14, 30, 33–
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aDOTS, Directly observed therapy short course
bNR Not reported
cNR Not reported
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observation.
Assessment of risk of bias in individual studies
Table 2 provides a detailed overview of items evaluated
against each study using the NOS statement, STROBE,
GRADE methodology, and Cochrane domains to assess
the risk of bias within and across studies. Six studies[36–40, 42] were evaluated as having low quality and the
rest of the studies have very low quality. Only four studies
[6, 40–42] had incomplete outcome data and six studies
[6, 31, 33, 35, 41, 42] have selective outcome reporting.
Results of individual studies
In Fig. 2, five studies [11, 30–32, 35] implementing
community-based treatment had treatment success rate




















Cox H 2014 4/19 VL N Y Y N Y A
Brust JC 2012 4/19 VL N Y N N N A, D
Vaghela JF 2015 4/19 VL N Y Y N Y A, D
Oyieng’o D 2012 4/19 VL N Y Y N N A, D
Joseph P 2011 4/19 VL N Y Y N N A, D
Van Deun A 2010 5/20 L N Y Y N Y A, D
Brust JC 2010 5/20 L N Y Y N Y A, D
Singla R 2009 4/19 VL N Y Y N Y A, D
Tupasi TE 2006 4/19 VL N Y Y N Y A, D
Thomas A 2007 4/19 VL N Y Y N Y A, D
Liu CH 2011 5/20 L N Y Y N Y A, D
Keshavjee S 2008 5/20 L N Y Y N Y A, D
Shin SS 2007 5/19 L N Y N N Y A, D
Cox HS 2007 4/19 VL N Y N N N A,D
Wei XL 2015 4/19 VL N Y Y N N A,D
Hirpa S 2013 5/20 L N Y N N N A, D
A Attrition bias, D Detection bias
VL Very Low: We are very uncertain about the estimate
L Low: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate
H High: Further research is very unlikely to change our confidence in the estimate of effect
NOS score < 4: Low quality
NOS score 4–5: Moderate quality
Y: Low risk of bias
N: High risk of bias
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studies [37–39, 42] utilizing traditional hospitalization
had treatment success rate less than the overall treat-
ment success rate of 56.9 %. The p value for heterogen-
eity was <0.001, with I2 = 85.60 %, indicating a
significant heterogeneity among studies. Four studies
[31–33] reported treatment failure rates higher than the
overall summary estimate of 6.5 % for community-based
studies and 3 studies [37, 38, 42] utilizing traditional
hospitalization had treatment failure rates above its
overall estimate of 18.8 %, with significant heterogeneity
(p = <0.001, I2 = 97.24 %).
Synthesis of results
Pooled estimates of treatment success and failure rates
were calculated as shown in Figs. 2 and 3 for community-
based treatment and traditional hospitalization. The pooled
probability of being cured and completing treatment using
a community-based treatment is 67.8 % (95 % CI: 0.593 to
0.762) compared with traditional hospitalization at 56.9 %
(95 % CI: 0.44.3 to 0.695). All studies equally contributed
to the heterogeneity of the pooled estimate; thus, there was
no need to investigate studies contributing to the
heterogeneity.Figure 3 shows the meta-analysis of treatment failure
rate for community-based treatment and traditional
hospitalization. The probability of MDR-TB and XDR-TB
patients failing treatment in community-based treatment is
6.5 % (95 % CI: 0.03 to 0.10; p < 0.01) compared to trad-
itional hospitalization at 18.8 % (95 % CI: 0.10 to 0.28; p <
0.01). There is an extremely high amount of heterogeneity
of treatment failure for community-based treatment (I2 =
71.90 %, p < 0.001) and traditional hospitalization (I2 =
97.24 %, p < 0.001), where a high level of heterogeneity of
I2 > 50 % is considered to be substantial [43].
Subgroup analysis
Since an extremely high heterogeneity was observed, sub-
group analysis of study and intervention characteristics was
conducted and presented in Table 3. Studies without HIV
co-infected [14, 30, 33–35] patients (72 %, 95 % CI: 0.65 to
0.79) reported higher treatment success rate than studies
with HIV co-infected [6, 11, 30, 32, 35, 37–40, 42] patients
(57 %, 95 % CI: 0.49 to 0.64). In addition, the 95 % CI for
studies with these characteristics: duration of DOTS-plus,
length of treatment, and number of drugs in regimen were
non-overlapping indicating a statistically significantly rela-
tionship with treatment success. However, the 95 % CI
Fig. 2 Pooled treatment success rate (cured and treatment completed) of MDR-TB and XDR-TB community-based intervention versus traditional
hospitalization. The pooled treatment success rate for community-based studies (a) is higher than studies that utilized the traditional
hospitalization (b) for treatment of MDR-TB and XDR-TB cases
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DOTS-plus provider, patient type, type of treated patients,
adverse events, quality of studies, and start year of studies,
thus, indicating studies with these characteristics are not
significantly different.
Meta-regression analysis
Table 4 shows the results from meta-regression ana-
lysis on continuous covariates that are independently
associated with outcomes. For community-based stud-
ies, results suggest that as age of patients’ increases,
treatment success rates of patients’ decreases by3.1 % (β:-0.031, 95 % CI:-0.044 to -0.019, p < 0.001).
We found a significant interaction between treatment
success and lost to follow up (β:0.009, 95 % CI:0.005
to 0.014, p < 0.001). Furthermore, an increase in treat-
ment length moderated an increase in treatment suc-
cess rate (β:0.020, 95%CI:0.007 to 0.033, p < 0.01).
Sensitivity analysis and publication bias
We found conflicting results between Egger’s and Begg’s
test. Egger’s test indicated asymmetrical distribution
(intercept = 4.04, 95 % CI: 0.791 to 7.290, p = 0.018)
while Begg’s adjusted rank correlation test (p = 0.192)
Fig. 3 Pooled treatment failure rate of MDR-TB and XDR-TB community-based intervention versus traditional hospitalization. The pooled treatment failure
rate for community-based (a) is lower than that of traditional hospitalization (b)
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analysis was conducted by repeating the meta-analysis
using the trim and fill method to assess the effect of
studies on the overall pooled estimate. In the trim and
fill method, no missing study was trimmed (Point esti-
mate = 0.634, 95 % CI: 0.557 to 0.705) (Fig. 4). Figure 4
shows funnel plot asymmetry arising from heterogeneity
that is due entirely to their being distinct subgroups of
studies, each with a different intervention effect. For
studies implementing traditional hospitalization, one
study was trimmed (Point estimate = 0.599, 95 % CI:
0.472 to 0.615) while no study was trimmed for
community-based interventions (Point estimate = 0.681,
95 % CI: 0.593 to 0.685) (Fig. 4).
Discussion
Summary of evidence
This review combined data from 16 observational stud-
ies from 9 MDR-TB HBC. Across these studies, theoverall sample size was 3344 MDR-TB and XDR-TB pa-
tients receiving second line anti-TB drugs. We compared
the effect of community-based treatment with traditional
hospitalization in improving treatment success rates
among MDR-TB and XDR-TB patients in the 27 MDR-
TB HBC. Our findings suggest that community-based
treatment improved treatment success rate than trad-
itional hospitalization methods.
All the studies reported outcomes on treatment suc-
cess rate. According to the WHO Global Tuberculosis
Report of 2015, only three MDR-TB high burden coun-
tries (Estonia, Ethiopia, and Myanmar) achieved a treat-
ment success rate of ≥ 75 %, which equals the overall
estimate in our study [1]. The study by Brust [12] re-
ported the highest treatment success rate (84 %) using
community-based treatment. However, with a very low
quality of evidence and small sample size (n = 80), were
having much confidence in the result may be debatable.
Amongst the seven studies that implemented a traditional
Table 3 Results from sub group analysis on treatment success
Variables # of Studies Point Estimate 95 % CI
Start year of study
2000 or later [6, 11, 14, 30, 33–35, 38–42] 12 0.64 0.54 0.74
1999 or earlier [31, 32, 36, 37] 4 0.60 0.44 0.77
Quality of study
Very Low [6, 11, 14, 30–35, 39, 41] 11 0.65 0.54 0.75
Low [36–38, 40, 42] 5 0.59 0.44 0.74
Adverse Events
< 50 % [34–36] 3 0.76 0.70 0.82
> 50 % [6, 31–33, 38, 40–42] 8 0.63 0.52 0.73
Type of treated patients
New cases and previously treated [6, 30–32, 34–37, 39, 41, 42] 11 0.61 0.52 0.71
Previously treated patients [11, 33, 38, 40] 4 0.66 0.53 0.78
HIV co-infected patientsa
Yes [6, 11, 30, 32, 35, 37–40, 42] 10 0.57 0.49 0.64
No [14, 30, 33–35] 6 0.72 0.65 0.79
Patient type
MDR [6, 11, 14, 31, 33–36, 39–42] 12 0.67 0.56 0.78
MDR and XDR [30, 32, 37] 3 0.51 0.48 0.55
XDR [38] 1 0.48 0.30 0.66
DOTS-plus Provider
Healthcare workers [30–32, 36, 38, 40–42] 8 0.59 0.48 0.69
Home care support teams & Family [6, 11] 2 0.78 0.60 0.95
Home care support teams [14] 1 0.71 0.62 0.80
Healthcare workers & Family [33, 35] 2 0.72 0.61 0.83
Family [34] 1 0.79 0.72 0.86
Drug Regimen Model
Standardized [6, 11, 30, 33–36, 39, 42] 9 0.66 0.53 0.79
Individualized [31, 32, 37, 38, 40, 41] 6 0.57 0.51 0.62
DOTS-plus Location
Health center [14, 30, 33, 34] 4 0.70 0.56 0.84
Patient home [6] 1 0.84 0.76 0.92
Patient home and Health center [11, 31, 32, 35] 4 0.61 0.53 0.68
Hospital [36–42] 7 0.57 0.44 0.69
Duration of DOTS-plusa
Throughout therapy [6, 11, 14, 30, 33–36, 40] 9 0.72 0.65 0.79
Partial observation [31, 32, 38, 39, 42] 5 0.50 0.43 0.57
Length of treatment (months)a
< 18 [32, 42] 2 0.48 0.42 0.55
18 & above [6, 11, 14, 30–35, 37, 39–41] 12 0.65 0.56 0.74
Drugs in regimena
5 [11, 30–32, 34, 35, 37–39, 41, 42] 11 0.57 0.49 0.64
> 5 [6, 33] 2 0.82 0.76 0.89
aNon-overlapping 95 % CI
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Table 4 Meta regression analysis of included in studies
implementing community-based treatment
Variables Coefficients 95 % CI P-value
Age −0.031 −0.044 −0.019 <0.001
Lost to follow up 0.009 0.005 0.014 <0.001
Adverse rate 0.005 0.003 0.006 <0.001
Treatment length 0.020 0.007 0.033 0.003
Omnibus p value: 0.000
Fig. 4 Illustration of funnel plot asymmetry due to heterogeneity. The figu
studies (a), community based studies (b), and hospital based studies (c)
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from 43.5 % [39] to 78.2 % [36].
Across the included studies, the pooled treatment fail-
ure estimate ranged from 6.5 % and 18.8 % for
community-based and traditional hospitalization re-
spectively. Treatment failure rates were generally lower
in community-based treatments compared to traditional
hospitalization treatments. We observed extremely low
treatment failure rates in studies by Singla [34] and
Brust [12] at 3 % and the failure rate in Keshavjee [38] at
31 % [6, 34, 38]. Our findings show a lower estimatere shows the Funnel plot of standard error by logit event rate for all
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[1] where 10 % of XDR-TB patients in 40 countries for
whom outcomes were reported failed treatment.
Furthermore, we found that studies with significant
patient and treatment characteristics significantly influ-
enced treatment success rate. In the meta-regression
model of treatment success, age, adverse rate and lost to
follow up could possibly explain the extremely high het-
erogeneity observed, although, inferences from statistical
heterogeneity may be uncertain.
Since there is a considerable high amount of heterogen-
eity (>75 %) between the study populations and varying
sampling methods, there is a low confidence that this is
the true population effect or that there even is a meaning-
ful single effect. Statistical heterogeneity may arise because
of clinical differences between studies (i.e. setting, types of
participants, or implementation of the intervention) or
methodological differences [44]. The extremely high het-
erogeneity observed from treatment outcomes studied
could be as a result of combining studies with a mix of
intervention components or controlling for different con-
founders. In addition, a plausible explanation to the high
heterogeneity could be the diverse characteristics in the
study settings. Despite an extensive search, studies from
other HBC were not located. Likewise, differences in
methodological quality may also cause heterogeneity and
lead to funnel plot asymmetry. Smaller studies tend to be
conducted and analyzed with less methodological rigor
than larger studies [44].
Agreements and disagreements with other studies or
reviews
Treatment outcomes among patients with MDR-TB
have been previously assessed [19, 45–47]. Two studies
[5, 16] compared the effectiveness of centralized versus
decentralized MDR-TB treatment. The treatment suc-
cess rate (68 %) in this review is slightly higher than the
estimate reported in the latest systematic review pub-
lished in 2014, which showed a treatment success rate of
65 % in community-based treatments [19]. Furthermore,
our result is slightly higher than that obtained from an
individual study by Loveday et. al which obtained a
treatment success rate of 58 % using community-based
treatment [15].
Overall, we observed a higher treatment success rate in
patients treated with standardized drug regimen than indi-
vidualized drug regimen, however, this was not significantly
different. Our findings are similar to that reported by Weiss
[19]. On the contrary, a review by Orenstein [48] reported
higher treatment success rate in patients treated with indi-
vidualized regimen than standardized regimen. Further-
more, studies with duration of treatment > 18 months
reported a higher treatment success rate than studies <
18 months of treatment. Our finding is similar to that fromWHO guidelines for the programmatic management of
DR-TB where patients previously treated with MDR regi-
men for a total duration of > 24 months were more success-
ful than <24 months [47]. Although, we focused our
analysis on the continuation phase, however, we found that
treatment success rate was significantly higher when treat-
ment duration was 18 months and above.
Limitations
There are several limitations to this study. First, the
pooled results of estimates may not be generalizable to
all the 27 MDR-TB HBC as only 9 countries are repre-
sented in our review. Additionally, these pooled rates
may not represent all MDR-TB and XDR-TB patients in
sampled countries where only small sample sized studies
have been done. Secondly, eligible studies utilized before
and after study design, which significantly reduced the
quality of our results and limited the comparability of
findings. Furthermore, among the included studies, not
all desired outcomes reported time points of treatment
outcomes, thus limiting analysis to studies with available
information.
Although, our meta-regression analysis explained het-
erogeneity, community-based treatment is a multifactor-
ial intervention and other factors could interfere with
treatment success, treatment failure, and high hetero-
geneity. Thus, the possibility of residual heterogeneity
may exist [27] and it cannot be ascertained whether vari-
ables included in the model are sources of bias. The
number of covariates was limited to avoid the problem
of multiplicity and false-positive results [26]. However,
despite these limitations it appears that community-
based treatment significantly improved treatment suc-
cess rates in DR-TB patients.
Conclusion
The pooled estimate for treatment outcomes in our study
indicates extremely high heterogeneity among studies,
which is statistically significant. The evidence indicated
that treatment success was significant among subgroups
with certain study and treatment characteristics.
Implications for practice
In this review, we examined the effects of subgroups
and meta-regression on treatment outcomes. In view
of the limited data on MDR-TB and XDR-TB from
other MDR-TB HBC, we have identified community-
based treatment to improve treatment outcomes in
MDR-TB and XDR-TB patients. Our findings here
further strengthen the need for decentralizing MDR-TB
treatment, integrating patient centered care, and financing
for TB treatment to expand community-based treatment
interventions. Community-based treatment can be tailored
to suit diverse settings as well as patient and treatment
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plore implementing community-based treatment rather
than traditional hospitalization in MDR-TB and XDR-
TB patients.
Implications for research
Due to poor quality of included studies, well-designed
studies are needed to further establish the impact of
community-based management on TB treatment out-
comes. Specifically, future studies should measure and re-
port time points of data collection on treatment outcomes
and detailed description of intervention components.
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